How does this company make money?
Every time the Madison laboratory completes an analysis and delivers a result to the ordering physician, the company bills CMS or a commercial insurer approximately $508. Revenue is recognized at that moment of delivery. There is no subscription, no hardware sale, and no other revenue stream — the business runs entirely on that per-test payment.
What makes this company hard to replace?
A physician's office that wanted to switch to a different DNA-based stool test would need to retrain staff on new sample collection steps and new patient counseling scripts. The Epic and Cerner electronic health record connections that currently route orders and results for Cologuard would need custom technical work to connect to a different provider. And because CMS reimbursement codes are assigned specifically to Cologuard, payers would need to build entirely separate administrative pathways before they could cover an alternative test.
What limits this company?
Every sample from every patient in the country must go to one building in Madison, Wisconsin — because that is the only facility certified to run the FDA-approved SEPT9-plus-hemoglobin protocol. The lab can currently handle more than 4 million samples a year, but that physical ceiling is the company's revenue ceiling. If anything disrupts that one location, the entire national testing pipeline stops.
What does this company depend on?
The company cannot operate without five things: FDA approval naming Cologuard as a primary colorectal cancer screening test; UPS to collect and transport samples nationwide; the reagents and instruments used to detect methylated SEPT9 DNA; the chemistry used to detect hemoglobin through FIT analysis; and CMS reimbursement coverage paying approximately $508 per test.
Who depends on this company?
Primary care physicians rely on it as the main non-invasive screening option for patients who refuse a colonoscopy — if it disappeared, those patients would have no comparable alternative. Gastroenterologists would see fewer referrals, because many of their colonoscopy patients arrive as Cologuard-positive cases needing follow-up. CMS and commercial insurers would face higher costs downstream, because cancers caught late are far more expensive to treat than those caught early through screening.
How does this company scale?
Within the Madison laboratory, the workflows for extracting and analyzing DNA replicate efficiently as more samples arrive — processing more tests does not require rebuilding the process from scratch each time. What does not scale easily is the physical space and the people. Clean-room facilities must be carefully expanded, and the technicians who handle biological samples under FDA-mandated quality conditions take time to train. Those two things stay as the bottleneck even as demand grows.
What external forces can significantly affect this company?
CMS sets the reimbursement rate at approximately $508 per test, and any policy decision to lower that rate directly squeezes the economics of every test the company runs. USPSTF guideline changes could expand or shrink the pool of patients eligible for stool-based DNA screening, which would directly grow or cut order volume. The continued growth of Medicare Advantage plans moves reimbursement away from the fixed CMS rate toward negotiated commercial rates, which introduces uncertainty into per-test revenue.
Where is this company structurally vulnerable?
If USPSTF — the government panel that sets cancer screening guidelines — narrowed the population eligible for stool-based DNA testing, or if the FDA revised Cologuard's approved label because a competitor's clinical trial showed a different method works better, the damage would hit twice at once. The approved indication and the CMS reimbursement code are both tied to the same named SEPT9-plus-hemoglobin methodology, so a change to one pulls the other down with it.
CompanyGraph